Th2 Cytokine mRNA Expression in Skin in Cutaneous T-Cell Lymphoma  by Vowels, Benjamin R et al.
Th2 Cytokine mRNA Expression in Skin 
in Cutaneous T-Cell Lymphoma 
Benjamin R. Vowels, Stuart R. Lessin, Maureen Cassin, Christine Jaworsky , Bernice Benoit, Jonathan T. 
Wolfe, and Alain H. Rook 
The Cutaneous T Cell Lymphoma Group, Department of Dermatology, University of Pennsylvania , School of Medicinc, Philadelphia, 
Pennsylvania, U.S.A. 
We have previously demonstrated that peripheral 
blood mononuclear cells from patients with Sezary 
syndrome, the leukemic form of cutaneous T-cell 
lymphoma which is accompanied by erythroderma 
and lymphadenopathy, have a Th2 cell cytokine [inter-
leukin 4 (IL-4) and interleukin 5] production pattern. 
In this study, we extend these observations to demon-
strate a correlation of the presence of a Th2 cytokine 
pattern with a malignant T-cell clone in different 
stages of cutaneous involvement among patients with 
cutaneous T-cell lymphoma (CTCL). Skin biopsies 
were obtained from 12 CTCL patients with various 
disease stages (three patch, three plaque, six tumor), 
three patients with parapsoriasis, four patients with 
inflammatory dermatoses, including two psoriasis and 
two lichen planus, and 12 normal controls. Total RNA 
was extracted, reverse transcribed, and PCR amplified 
with IL-2, IL-4, IL-5, interferon gamma (IFN-y), and 
ft-actin oligonucleotide primers. Although all skin 
specimens tested had detectable IL-2 and IFN-y 
rnRNA, only specimens from patients with CTCL 
D istinct subsets ofT helper cells, which are delineated on the basis of cytokine-secretion patterns, were ini-tially described in the murine immune system [1-3). It has become increasingly clear that such subsets of T cells, termed Th 1 and Th2, can also be identi-
fied in humans (4). Although the first evidence ofTh 1 and Th2 cells 
in humans came from cell lines or T-cell clones [5 ,6), recent evi-
dence indicates that these subsets are an important component of the 
specific T-cell response in several different diseases. Infiltrates of 
interleukin 4 (IL-4) - and IL-5 -producing cells (Th2 phenotype) 
that do not produce IL-2 or interferon-y (IFN-Y) have been de-
scribed in atopic individuals in response to dust-mite allergen [7,8). 
Bronchial lavage fluids from asthma patients have been shown to 
contain significantly more Th2-like cells than control subjects (9). 
Moreover, Yamamura et al have shown using the polymerase chain 
reaction (PCR) that T cells obtained from lepromatous-type lesions 
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or parapsoriasis had demonstrable IL-4 and/or IL-5 
mRNA. Specifically, IL-5 mRNA was detected in skin 
biopsies from five of six tumor-stage CTCL, two of 
three plaque-stage CTCL, one of three patch-stage 
CTCL, and 1 of 3 parapsoriasis patients, whereas IL-4 
mRNA was demonstrated to be present in five of six 
tumor-stage, one of three plaque stage, none of three 
patch-stage CTCL, and none of three parapsoriasis pa-
tients. These results indicate that in all stages of cuta-
neous involvement of CTCL, encompassing patch 
stage through tumor stage, IL-4 and IL-5 mRNA is 
variably detectable. In tumor-stage skin lesions, typi-
cally characterized by a dense dermal infiltrate of ma-
lignant T cells, Th2 cytokine mRNA is virtually always 
detectable. The ability to detect Th2 cytokine mRNA 
in the skin of patients with CTCL supports our 
previous findings that the malignant T cells in CTCL 
possess a Th2-helper cell phenotype. Key words: Sezary 
syndrome/skin neoplasms/mononuclear leukocytes/interleu-
kin.] Invest Dermato1103:669-673, 1994 
of leprosy patients were positive for IL-4, IL-S, and IL-I0 mRNA, 
the Th2 phenotype, whereas T cells from tuberculoid-like lesions 
produced cytokine mRNA consistent with the Th 1 phenotype 
(IFN-y and IL-2) (10). Parasitic infection, particularly with hel-
minths, has also been shown to evoke a Th2-like cell response (11). 
In addition, activation of T cells via the chemical induction of 
autoimmunity or graft-versus-host disease in rodents appears to 
most often result in a Th2 cell pattern (reviewed by Goldman et al 
[12]). Although the immunologic factors that lead to the generation 
of a specific T -helper subset response remain to be defined, it ap-
pears that Th l-like cells are primarily responsible for mediating 
delayed-type - hypersensitivity reactions such as that observed in 
response to certain infections or contact dermati tis , whereas a Th2-
like response is observed in conditions such as parasitic or allergic 
reactions characterized by eosinophilia and high-antibody titers, 
particularly 19B. 
Patients with Sezary syndrome (SzS), a leukemic form of cutane-
ous T-cell lymphoma (CTCL) characterized by malignant atypical 
CD4+jCD45RO+ lymphocytes (Sezary cells) in the skin and pe-
ripheral blood, in addition to erythroderma, exhibit an array of 
immunologic abnormalities that parallel the ill "ilro activities of 
Th2 cytokines, particularly IL-4 and IL-5 (13) . We have previously 
shown that peripheral blood monolluclear cells (PBMe) from SzS 
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Table I. Comparative Features of Parapsoriasis and Cutaneous T-Cell Lymphoma (CTCL) 
Clinical 
Presentation 
Routine 
Histology 
Cell Marker 
Analysis 
Buffy Coat 
Analysis 
Parapsoriasis Persistent erythematous 
scaly patches; trunk 
and extremities 
Individually disposed lympho-
cytes in a llon-spongiotic epi-
dermis; sclerotic papillary 
dermal collagen splayed by 
lymphocytes; hyperconvolu-
tion of lymphocyte nuclei 
variable 
No loss of pan-T-cell matura-
tion antigens; may have ad-
mixture of CD4+ and 
CD8+ cells in the epidermis 
and dermis 
0- 5% Sezary cells in 
mononuclear component 
of peripheral blood 
Patch-stage 
CTCL 
Erythematous scaly 
asymmetric patches 
with irregular 
borders; trunk and 
extremities> acral 
skin 
Individually disposed and nested 
lymphocytes in a non-spon-
giotic epiderm.is, many with 
hyperconvoluted nuclear con-
tours; sparse dermal infiltrate 
CD4+: CD8+ cells in the epi-
dermis exceed 6: 1; CD4+ 
cells show partial loss of pan-
T cell maturation antigens 
(CD2,3+/-5); dermal com-
ponent reactive 
From 0 up to 15% Sezary 
cells in the mononuclear 
component of peripheral 
blood 
Plaque-stage 
CTCL 
Infiltrated plaques with 
bizarre arcuate 
borders; trunk and 
extremities, also head 
and neck 
Nested lymphocyte with hyper-
convoluted nuclear contours 
in the epidermis and within 
the superficial dermal stroma 
CD4+: CD8+ cells exceed 6: 1 
in both the epidermis and 
dermis; there is also loss of 
pan - T-cell maturation anti-
gen in both sites 
Sezary cell count < 15% 
su ggests disease localized 
to skin; if> 15%, sys-
temic involvement present 
Tumor-stage 
CTCL 
Exophytic nodules ± 
ulceration anywhere 
on the body 
Epidermotropism of lympho-
cytes usually lacking; nodules 
of abnormal lymphocytes 
(may show blast transforma-
tion) in the dermis; may be 
surrounded by a cuff of reac-
tive lymphocytes 
Tumor nodules show prepon-
derance of CD4+ cells that 
have loss of 1 or more pan-
T-cell maturation antigens 
Sezary cell coum < 15% 
suggests disease local ized 
to skin; if> 15%, sys-
temic involvement present 
Sezary syndrome 
(leukemic 
form of 
CTCL) 
Generalized erythro-
derma with scaling, 
often with marked 
pruritus 
Not diagnostic 
patients produce a Th2 cell pattern of cytokine secretion following 
mitogen-stimulation [14] . Although in that study the source of the 
Th2 cytokines could not specifically be attributred to the malignant 
T cell, we observed a direct correlation between the number of 
Sezary cells and the amount of IL-4 produced, and an inverse corre-
lation between the number of Sezary cells and the production of 
IL-2 and IFN-y. 
In the present study, we show that these observations can be 
extended to the detection of Th2 cytokine mRNA in the skin of 
CTCL patients. Furthermore, we demonstrate that as CTCL pro-
gresses from patch to tumor stage, i.e., as the extent of the malignant 
T-cell infiltrate becomes more marked, the prevalence ofTh2 cyto-
kine mRNA in the skin is more frequent. 
MATERIALS AND METHODS 
Patients and Skin Samples Patients participating in this study were 
diagnosed with CTCL based on clinical, histopathologic, and immunohis-
tologic criteria [Table I] (reviewed in [15]). Skin samples, consisting of 
4-mm punch biopsies, were obtained from CTCL patients with different 
stages of cutaneous involvement (patch, plaque, or tumor), or from volun-
teers with other skin disorders characterized by lymphoid infiltrates includ-
ing parapsoriasis, lichen planus, and psoriasis. Skin biopsies were also ob-
tained from normal controls. All CTCL patients were seronegative for 
human T-cell lymphocytic virus-I antibodies by enzyme-linked immuno-
sorbent assay and had no apparent secondary infections or other dermato-
logic diseases. All skin samples were procured after informed consent was 
obtained. 
Extraction of RNA and Performance of the Polymerase Chain Re-
action (peR) Total RNA was extracted from skin biopsies, fresh or snap 
frozen, using RNAzol B (Tel-Test, Inc. , Friendswood, TX), a modification 
of the guanidinium thiocyanate isolation method [16]. Following extrac-
tion, the RNA was reverse transcribed (RT) as previously described [17]. 
Briefly, 3 J.!g of total RNA, after brief denaturation at 65"C for 5 min, was 
incubated at 37"C for 30 min in a cocktail containing RT (BRL/Gibco), 
deoxynucleotide triphosphates (dNTP, Perkin-Elmer Cetus), oligo (dT), 6 
(Sigma), dithiothreitol (BRL), RNase inhibitor (RNAsin, BRL), MgCl2, 
KCI, and Tris buffer in a total volume of20 J.!l. Immediately following RT, 
10 J.!I of the RT cocktail was removed for PCR amplification. PCR amplifi-
cation of cytokine eDNA was accomplished using sense and antisense 
Not diagnostic Sezary cell count> 15%, 
usually much higher 
primers based on previously published sequence data and by selection using a 
primer selection program, OSP [18] (Table II) . To prevent amplification of 
any contaminating genomic DNA, all cytokine primers were designed to 
span introns. To verify the integrity of the RNA and cDNA for each experi-
mental sample, a separate control amplification using p-actin primers was 
included in the PCR run. The PCR cocktai l consisted ofTris buffer, 2.5 mM 
MgCI2' 1.5 mM dNTP, 500 ng each of the sense and antisense primers, 1.25 
U ofTaq polymerase (Promega), and deionized water in a total volume of 50 
J.!l. This PCR cocktail was amplified in a forced - hot-air thermocycler 
(BioOven II, BioTherm Corp., Fairfax, VA) for 30 cycles where a single 
cycle consisted of92"C for 1 min, 55 °C for 1 min, and 72°C for 1.5 min. To 
avoid carry-over contamination, strict physical and procedural precautions 
(separate handling areas and dedicated supplies and reagents for pre- and 
post-amplification) were routinely observed. To monitor for carry-over 
contamination, a negative control water blank was included in each PCR 
amplification. Following amplification, a 12-J.!1 sample of the PCR cocktail 
is sized on a ethidium bromide -containing 3% Nusieve (FMC, Rockland, 
ME): 1 % agarose (Gibco/BRL) gel run at 90 V for 1 h. The gel was visual-
ized under ultraviolet light and the size of any bands present are compared to 
molecular weight markers run in a parallel lane. The specific cytokine iden-
tity of PCR products was verified by size and by autoradiography using a 
32P-a-ATP - labeled nested oligonucleotide probe (Table II) . 
RESULTS 
Thl Cytokine (IL-2 and IFN-Y) mRNA Expression in Nor-
mal Skin To evaluate cytokine expression in CTCL, we initially 
determined the background expression of cytokine mRNA in nor-
mal skin. PCR analysis revealed that skin samples from 12 different 
normal donors all expressed mRNA for IL-2 and IFN-y; however, 
IL-4 or IL-5 mRNA was not detected within any of these specimens 
(Table ill and Fig 1). It should be stressed that neither IL-2 nor 
IFN-y mRNA were detected in negative control cDNAfrom HuT 
78 cells, a CD4+-transformed T-cell line, or in the negative-con-
trol water blanks, indicating that the results obtained in skin samples 
were not the result of PCR contamination. Thus, normal skin ex-
hibited a Th 1 cytokine pattern. 
Th2 Cytokine (IL-4 and IL-S) lI1RNA in Skin Biopsies from 
CTCL Patients Biopsies of involved skin from CTCL patients 
VOL. 103, NO.5 NOVEMBER 1994 Th2 CYTOKINE mRNA EXPRESSION IN CTCL 671 
Table II. Oligonucleotides used for PCR and as Probes 
Bascpair Location 
Target cDNA Primer incDNA 
IL-2 
Sense 12-33 
Antisense 500-479 
Nested 384-366 
IL-4 
Sense 86-103 
Antisense 481-462 
Nested 409-385 
IL-5 
Sense 45-64 
Antisense 449-430 
Nested 250-227 
IFN-y 
Sense 142-161 
Antisense 497-478 
Nested 419-401 
p-actin 
Sense 285-302 
Antisense 888-871 
Nested 703-684 
were obtained for evaluation of IL-4 and IL-S mRNA expression. 
Specimens were segregated into three separate groups based upon 
clinicopathologic characterization of lesional skin (Table I) and 
consisted of patch stage (n = 3), plaque stage (n = 3), and tumor 
stage (n = 6) . In addition, biopsies were taken from patients diag-
nosed with parapsoriasis (n = 3), a frequent precursor of CTCL 
[19] . Biopsies from patients with patch-stage disease, the earliest 
stage of CTCL, did not express IL-4 mRNA; however, involved 
skin from one patient did express IL-S mRNA (Table IV). In biop-
sies of plaque-stage disease, one of three specimens expressed IL-4 
mRNA, whereas two of three specimens, including the one ex-
pressing IL-4 mRNA, had detectable mRNA for IL-S (Table IV). 
In the most advanced stage of CTCL, tumor stage, IL-4 mRNA was 
detected in all six patients evaluated and IL-S mRNA was present in 
five of six patients (Table IV) . The biopsies from parapsoriasis 
patients demonstrated a similar pattern to that observed within the 
samples from the patch-stage CTCL patients, with none of three 
expressing IL-4 mRNA and one of three having detectable IL-S 
mRNA (Table IV). 
Non-CTCL Lymphoid Infiltrates, Lichen Planus, and Psori-
asis Express a Th1 Cytokine Profile Skin samples were also 
analyzed from volunteers with benign inflammatory dermatoses 
unrelated to CTCL characterized by the presence of heavy dermal 
mononuclear cell infi ltrates (psoriasis, n = 2; lichen planus, n = 2). 
In all four of these specimens, both IFN-y and IL-2 mRNA were 
detected. However, in contrast to the findings in CTCL, neither 
IL-4 nor IL-S mRNA was detected in any of the psoriasis or lichen 
planus biopsies (Table III) . 
DISCUSSION 
We have previously shown that PBMC from SzS patients produce 
increased amounts of IL-4 with a concomitant decrease in IL-2 and 
IFN-y production as compared to normal controls [14] . The amount 
Table III. Expression of Cytokine mRNA 
in Non-CTCL Skin 
Patient Dx n IL-4 IL-5 IFN-y IL-2 p-Actin 
Normal Control 
Trunk 5 + + + 
Arm, face 7 + + + 
Psoriasis 2 + + + 
Lichen planus 2 + + + 
Oligonucleotide Sequence (5' -4 3') 
TAA TCA CTA CTC ACA TGA ACC T 
TGT TGA GAT GAT GCT TTG ACA 
CTA TTA CGT TGA TAT TGC T 
TCC CCC CTC TGT TCT TCC 
GCC TTT CCA CGC CGT TTT CC 
CGA GAG GAT CCT GTC GAG CCG TTT 
ATG AGG ATG CTT CTG CAT TTG 
TCA ACT TTC TAT TAT CCA CTC 
TGA AAG ATT TCT TCA GTG CAC AGT 
AGT TAT ATC TTG GCT TTT CA 
ACC GAA TAA TTA GTC AGC TT 
CTT GAT GGT CTC CAC ACT CT 
ATG GAG AAA ATC TGG CAC 
TGA TGG AGT TGA AGG TAG 
AGG GCG ACG TAG CAC AGC TT 
oflL-4 produced correlated with the numbers of circulating Sezary 
cells. Furthermore, we have demonstrated the abi lity of exogenous 
IFN-y to inhibit the increased IL-4 production by the PBMC from 
SzS patients [1 4]. To extend these data and to investigate further the 
apparent Th2 cytokine pattern in CTCL, we studied the expression 
ofThl and Th2 cytokine mRNA in skin lesions from patients with 
different stages of CTCL. We demonstrate in this study the abil ity 
to detect Th2 cytokine mRNA in skin lesions from CTCL patients 
at all stages of disease encompassing patch stage through tumor 
stage. However, either IL-4 or IL-S mRNA, or both, were more 
frequently detected in densely infiltrated lesions characteristic of a 
more advanced stage of disease. 
In addition to finding Th2 cytokine mRNA at various stages of 
disease, mRNA for both IL-2 and IFN-y was expressed in both 
normal and CTCL involved skin. It is unlikely that the amplifica-
tion of these two cytokines was the result of contamination of re-
agents because neither water blanks nor cDNA obtained from nor-
mal resting PBMCs or HuT78 cells showed amplification of these 
cytokines. Because there are no known endogenous skin cell s that 
produce IL-2 or IFN-y, either constitutively or by induction, these 
data suggest that skin-trafficking T cells, which are observed in 
perivascular regions of normal skin [20], may be primed to produce 
low levels of IL-2 and IFN-y. Furthermore, perivascular T cells in 
normal skin often express activation markers such as CD2S and class 
II HLA antigens [20]. Because IL-2 mRNA production precedes the 
expression of these activation markers in the normal kinetics of 
T-cell activation and proliferation [21], it is not surprising that 
mRNA for IL-2 or IFN-y is detectable by PCR in normal skin 
biopsies. 
Although RT-PCR ca nnot definitively determine the source of 
the T h2 cytokines in the involved skin of CTCL, several lines of 
evidence suggest that IL-4 and IL-S are being produced by the 
malignant T-cell clone. First, although the numbers of patients is 
small , there appears to be a correlation between the number and 
density of malignant T cells that invade the skin with each succes-
sive stage of disease and the likelihood that IL-4 and IL-S mRNA 
will be detected. Second , we have previously observed a correlation 
between the number of circulating malignant T lymphocytes and 
the amount of IL-4 produced upon activation of PBMCs from SzS 
patients [14] . Furthermore, PBMC fr0111 SzS patients in remission, 
as well as PBMC from plaque stage patients without circulating 
malignant T cells, produced IL-4 in amounts comparable to normal 
controls [14]. Nevertheless, the recent observation by Dummer and 
colleagues [22] that mitogen-activated PBMCs from plaque-stage 
patients lacking Sezary cells did produce variab ly increased amounts 
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Figure 1. PCR analysis of cytokine mRNAs isolated from 
skin lesions of CTCL patients and normal volunteers. Sam-
ples were analyzed for expression of IL-2, IFN -y, IL-4,I L-S , and 
p-actin mHNAs (see Materials a/Jd Methods). Representative results 
are shown. Positive and negative controls consisted of Concanava-
lin A- stimulated normal PBMCs and unstimulated HuT 78 cells, 
respectively. 
ofIL-4 suggests that some reactive lymphoid cells in CTCL may be 
contributing to Th2 cytokine production. 
Although our data suggest that the malignant T-cell clone is the 
source of T h2 cytokine mRNA, other cutaneous cellular sources 
cannot be ruled out by our studies. Several recent reports have dem-
onstrated that mas t cells can synthesize and secrete Th2 cytokines 
[23]; however, the lack of clinical and histopathologic evidence for 
mast cell degranulation in these patients suggests that mast cells are 
not likely to be the source ofIL-4 or IL-5. Another potential source 
of lL-5 in these samples are activated eosinophils, which Broide et al 
have recently shown to be capable of producing IL-5 [24] and are 
present in increased numbers in Sezary patients. Further investiga-
tion into the precise source of the Th2 cytokines is warranted, 
particularly with the use of more specific techniques, such as in situ 
hybridization, which would permit the precise localization of cyto-
kine mRNA. 
Althou gh we are able to detect Th2 cytokine mRNA in clinically 
involved skin specimens from a large proportion of patients with 
different histologic stages of CTCL, there are several potential rea-
sons for our fa ilure to detect this pattern in a greater percentage of 
specimens from early CTCL. One plausible explanation relates to 
Table IV. Expression of Th2 Cytokine mRNA in CTCL 
Skin 
Patient Stage IL-4 IL-S IFN-y IL-2 p-Actin 
PPI Parapsoriasis + + + 
PP2 Parapso riasis + + + + 
PP3 Parapsoriasis + + + 
PAl Patch + + + 
PA2 Patch + + + + 
PA3 Patch + + + 
PQI Plaque + + + 
PQ2 Plaque + + + + 
PQ3 Plaque + + + + + 
TU! T umor + + + + + 
TU2 Tumor + + + + + 
TU3 Tumor + + + + 
TU4 Tumor + + + + + 
TUS Tumor + + + + + 
TU6 Tumor + + + + + 
, >.-ti;~;~.-. 
IL-2 
. ;=. 
IL-4 
IFN-y 
IL-5 
393 kb 
220 kb 
the known interactions between Th 1 and Th2 cytokines, which 
appear to have reciprocal effects on the opposing T-helper subset, 
with IFN-y having the capacity to inhibit the expression of Th2 
cytokine gene expression [25]. Thus, in early skin lesions of CTCL, 
a sparse infiltrate of malignant T cell s is present upon a background 
of normal pre-existing, skin-traffi ckin g Th 1 cells that may play a 
role in the host immune response to suppress the activity and prolif-
eration of the malignant cells. In support of this, Wood and col-
leagues have demonstrated tumor-infiltrating CD8+ cytotoxic T 
cells in early CTCL [26]. Because cytotoxic T cells are a rich source 
of IFN-y production upon activation [27], it is likely that the 
tumor-infiltrating cells may also playa role in the suppression of the 
Th2 cytokine transcripts below levels that may be routinely de-
tected by our PCR assay. 
The demonstration of an immunologic milieu characterized by a 
predominance of Th 1 cytokines in early CTCL reflects the clinical 
and histologic findings at this stage of disease. IFN-y- mediated 
suppression of Th2 cell proliferation may be an important factor 
responsible for the indolent course of patch- and plaque-stage dis-
ease. Furthermore, the epidermal expression of intercellular adhe-
sion molecule- l (ICAM-l) is known to be an IFN-y-dependent 
event and is associated with the significant degree of epidermotro-
pism typical of early disease [28) . As lesions evolve and subsequently 
demonstrate dermal invasion characteristic of tumor-stage disease, 
both ICAM-l expression and the degree of epidermotropism be-
come less profound or completely absent. On the other hand, the 
aggressive course of advanced disease may result from enhanced 
tumor-cell proliferation mediated by autocrine stimulation of the 
numerous malignant cells by increased IL-4 production, which ad-
ditionally suppresses Th 1 cell responses. Thus, competing Th 1 and 
Th2 cytokine effects may be important not only in regard to the 
clinical phenotype and immune defects observed in CTCL [13), but 
disordered cytokine regu lation may also be an essential factor in the 
events critical to progression of disease . 
The presence of a cytokine imbalance that contributes to the 
progression of CTCL has important therapeutic implications. One 
obvious strategy might involve replacement of deficient Thl cyto-
kines via the administration of currently available recombinant pro-
teins. Limited trials of the use of IFN-y for CTCL have demon-
strated some clinical benefit of this cytokine [29) . More 
importantly, IFN-a, which also mediates Th 1 responses by a variety 
of mechanisms [30), has extremely potent biologic activity in the 
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treatment of CTCL [31] . We have noted the normalization of the 
cytokine profile in concert with the normalization of certain critical 
immune functions while experiencing a complete clinical remission 
during therapy with IFN-a among patients with Sezary syndrome 
and elevated IL-4 production [Vowels BR, Lessin SR, Cassin M, 
Benoit BM, Rook AH: Normalization of cytokine secretion pat-
terns and immune function following disappearance of malignant 
clone from the peripheral blood of a Sezary syndrome (SzS) patient 
(abstr).] Invest Dermato/100:556, 1993]. Thus, as additional critical 
immune factors are identified that favor the evolution of Th 1 re-
sponses, such as IL-12, which is a potent inducer ofThl responses 
([32], and Rook AH, Kubin M, Vonderheid EC, Cassin M, Vowels 
BR, Wolfe JT, Wolf S, Trinchieri G, Lessin SR: Interleukin-12 
(IL-12) reverses cytokine and immune abnormalities ofSezary syn-
drome (abstr). ] IlIlIest Dermato/102:557, 1994), their therapeutic 
application in CTCL may prove beneficial. 
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